{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:06:41Z","timestamp":1793164001963,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Radioiodine (\n                      <jats:sup>131<\/jats:sup>\n                      I) therapy in treatment of thyroid cancer, has a biological clearance that is significantly reduced in end-stage kidney disease (ESKD), leading to increased radiation exposure and potential myelotoxicity. For ESKD patients on haemodialysis (HD), there is no standardized approach to\n                      <jats:sup>131<\/jats:sup>\n                      I administration and subsequent HD schedule.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      Two patients with ESKD on HD were treated with\n                      <jats:sup>131<\/jats:sup>\n                      I therapy for thyroid cancer. Rationale for treatment and local\n                      <jats:sup>131<\/jats:sup>\n                      I treatment protocol modifications are discussed. Modifications were made to existing infrastructure and additional patient and staff safety precautions were undertaken, including serum radioactivity measurements to monitor for myelotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>\n                      HD at 24-,72- and 144-hours post-\n                      <jats:sup>131<\/jats:sup>\n                      I results in a retained radiation activity profile comparable to patients with normal renal function. Radiation dose to bone marrow throughout treatment was assessed at\u2009&lt;\u20090.3\u00a0Gy for both patients, within safe limits. The highest contribution of radiation dose to bone marrow (60% and 47% for patient 1 and patient 2 respectively) was due to the radioactivity retained in blood before the first HD session. Cumulative radiation exposure to dialysis staff was well within local safety constraints (300\u03bcSv per year) at 7\u03bcSv and 23\u03bcSv for patient 1 and 2 respectively. At 24\u00a0months post-therapy, thyroglobulin levels remained undetectable for both patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:sup>131<\/jats:sup>\n                      I therapy can be safely administered in patients with ESKD on HD with low-risk thyroid cancer through modifications to existing infrastructure and protocols. Serum radioactivity measurements is a simple and minimally invasive method to assess bone marrow safety during treatment. Ongoing pooling of experiences is needed to inform a standardized protocol for therapy in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04348-0","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T16:29:38Z","timestamp":1753720178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of radioiodine ablation therapy in haemodialysis patients with thyroid cancer: a case series of two patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Raymond","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra L.","family":"Malaroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"4348_CR1","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1210\/jc.2015-2124","volume":"100","author":"HT Prinsen","year":"2015","unstructured":"Prinsen HT, Klein Hesselink EN, Brouwers AH, Plukker JT, Sluiter WJ, van der Horst-schrivers AN, et al. Bone Marrow Function After (131)I Therapy in Patients With Differentiated Thyroid Carcinoma. J Clin Endocrinol Metab 2015;100:3911\u201317.","journal-title":"J Clin Endocrinol Metab"},{"key":"4348_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","volume":"35","author":"M Luster","year":"2008","unstructured":"Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941\u201359.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"4348_CR3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/ki.2008.95","volume":"73","author":"G Murcutt","year":"2008","unstructured":"Murcutt G, Edwards J, Boakye J, Davenport A.Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy. Kidney Int. 2008;73(11):1316\u201319.","journal-title":"Kidney Int"},{"key":"4348_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2967\/jnmt.121.261979","volume":"50","author":"M Kumar","year":"2022","unstructured":"Kumar M, Subramanian K, Tanwar KS, Prabhahar A, Divyaveer S, Sood A, et al. Radioiodine therapy in patient with differentiated thyroid cancer and end-stage renal disease on maintenance hemodialysis: case report with review of literature. J Nucl Med Technol 2022;50:228\u201332.","journal-title":"J Nucl Med Technol"},{"issue":"2","key":"4348_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2214\/AJR.19.22626","volume":"215","author":"A Ciarallo","year":"2020","unstructured":"Ciarallo A, Rivera J.Radioactive iodine therapy in differentiated thyroid cancer: 2020 update. AJR Am J Roentgenol. 2020;215(2):285\u201391.","journal-title":"AJR Am J Roentgenol"},{"key":"4348_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"4348_CR7","unstructured":"Radiation Protection and Safety of Radiation Sources: international Basic Safety Standards. Vienna: International Atomic Energy Agency; 2014."},{"key":"4348_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2967\/jnumed.119.232017","volume":"61","author":"M Vermandel","year":"2020","unstructured":"Vermandel M, Debruyne P, Beron A, Devos L, Talbot A, Legrand JF, et al. Management of Patients with Renal Failure Undergoing Dialysis During (131)I Therapy for Thyroid Cancer. J Nucl Med 2020;61:1161\u201370.","journal-title":"J Nucl Med"},{"issue":"7","key":"4348_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","volume":"35","author":"M Lassmann","year":"2008","unstructured":"Lassmann M, H\u00e4nscheid H, Chiesa C, Hindorf C, Flux G, Luster M.EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4348_CR10","first-page":"171","volume":"87","author":"RS Benua","year":"1962","unstructured":"Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171\u201382.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"issue":"3","key":"4348_CR11","first-page":"451","volume":"44","author":"R Dorn","year":"2003","unstructured":"Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA.Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44(3):451\u201356.","journal-title":"J Nucl Med"},{"issue":"12","key":"4348_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1089\/thy.2005.15.1321","volume":"15","author":"JP Holst","year":"2005","unstructured":"Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J.Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005;15(12):1321\u201331.","journal-title":"Thyroid"},{"issue":"12","key":"4348_CR13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/1097-0142(19901215)66:12<2509::AID-CNCR2820661211>3.0.CO;2-M","volume":"66","author":"DW Morrish","year":"1990","unstructured":"Morrish DW, Filipow LJ, McEwan AJ, Schmidt R, Murland KR, von Westarp C, Betcher KB.131I treatment of thyroid papillary carcinoma in a patient with renal failure. Cancer. 1990;66(12):2509\u201313.","journal-title":"Cancer"},{"issue":"6","key":"4348_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jjco\/hyf049","volume":"32","author":"N Magn\u00e9","year":"2002","unstructured":"Magn\u00e9 N, Magn\u00e9 J, Bracco J, Bussi\u00e8re F.Disposition of radioiodine (131)I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report. Jpn J Clin Oncol. 2002;32(6):202\u201305.","journal-title":"Jpn J Clin Oncol"},{"key":"4348_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/105072501753271716","volume":"11","author":"RG Jim\u00e9nez","year":"2001","unstructured":"Jim\u00e9nez RG, Moreno AS, Gonzalez EN, Sim\u00f3n FJL, Rodriguez JR, Jimenez JC, et al. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method. Thyroid 2001;11:1031\u201334.","journal-title":"Thyroid"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04348-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04348-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04348-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:45:03Z","timestamp":1757310303000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04348-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4348"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04348-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4161082\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols in the study were approved by the Nepean Blue Mountains Local Health District (NBMLHD) Low and Negligible Risk Subcommittee and ratified by the NBMLHD Human Research Ethics Committee (HREC 2022\/ETH01125) in accordance with National Health and Medical Research Council\u2019s \u201cNational Statement on Ethical Conduct in Human Research\u201d. Informed consent was obtained from all participants in this study prior to collection of any samples or data. The ethical process is consistent with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"420"}}